Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
10/24/2013 9:44:21 AM
NEW YORK and LONDON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo Jimenez, M.D., to the position of Chief Medical Officer. This appointment reflects Celsus' continued growth as the company advances the development of its lead clinical asset, MRX-6, a non-steroidal anti-inflammatory cream for the treatment of eczema and other skin inflammatory disorders.
Help employers find you! Check out all the jobs and post your resume.
comments powered by